Clinical Heterogeneity in Acute Symptomatic Seizures due to Autoimmune Encephalitis Related to GAD65 Antibodies

Neuroimmunomodulation. 2022;29(3):171-176. doi: 10.1159/000519229. Epub 2021 Nov 30.

Abstract

Introduction: This study aimed to explore the diversity and clinical features of acute symptomatic seizures due to autoimmune encephalitis related to anti-glutamate decarboxylase (GAD) 65 antibodies.

Methods: Clinical data of a series of 6 patients positive for anti-GAD65 antibodies were retrospectively analyzed.

Results: Five of the patients were male and 1 was a female, with a median age of 44.1 years (range 18-70 years). Seizure forms were varied in 6 patients when they were admitted to the hospital: 3 cases of seizures only and 3 accompanied by other symptoms, such as mental disorder, cognitive impairment, cerebellar ataxia, and ocular movement disorder. Three patients (50%) had coexisting systemic autoimmune diseases, including diabetes mellitus, vitiligo, and hyperthyroidism. Five patients (83%) had abnormal brain MRI findings. They were all treated by immunotherapy, 5 of 6 patients improved significantly but relapsed after withdrawing methylprednisolone, and 1 patient got deteriorated. None of them were diagnosed with tumors.

Conclusions: Clinical features of acute symptomatic seizures related to GAD65 antibodies are diverse, and early and continuous immunotherapy is necessary for patients.

Keywords: Acute symptomatic seizures; Autoimmune encephalitis; Glutamate decarboxylase 65 antibody.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Autoantibodies*
  • Encephalitis* / complications
  • Female
  • Hashimoto Disease
  • Humans
  • Immunologic Factors
  • Male
  • Middle Aged
  • Retrospective Studies
  • Seizures / etiology
  • Young Adult

Substances

  • Autoantibodies
  • Immunologic Factors

Supplementary concepts

  • Hashimoto's encephalitis